Adaptive Biotechnologies director sells 48,044 shares

Adaptive Biotechnologies Corp director Michelle Renee Griffin reported exercising stock options and selling shares.

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp director Michelle Renee Griffin reported exercising stock options and selling shares. On the same day, she exercised options for 48,044 shares of common stock at $3.99 per share, then sold 48,044 common shares at a weighted average price of $15.30, with individual trades ranging from $15.11 to $15.54. After these transactions, she directly owned 15,394 common shares. The option was fully vested and exercisable, and the trades were executed under a Rule 10b5-1 trading plan adopted on November 7, 2025.

Insider Trade Summary

Exercise and Sale: 48,044 shares ($543K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider GRIFFIN MICHELLE RENEE

Role Director

Sold 48,044 shs ($735K)

Approx. gross sale proceeds $735K

Approx. exercise cost $192K

Approx. pre-tax spread $543K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	48,044	$0.00	$0.00
Exercise	Common Stock	48,044	$3.99	$192K
Sale	Common Stock	48,044	$15.30	$735K

Holdings After Transaction: Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 15,394 shares (Direct)

Footnotes (3)

1. F1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025.
2. F2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.11 to $15.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
3. F3. The option is fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did ADPT director Michelle Renee Griffin report?

She exercised options for 48,044 shares and sold 48,044 common shares. The sale was executed at a weighted average price of $15.30, with individual trade prices ranging from $15.11 to $15.54, all on the same transaction date.

How many Adaptive Biotechnologies (ADPT) shares does the director hold after these trades?

After the reported transactions, Michelle Renee Griffin directly owns 15,394 shares of Adaptive Biotechnologies common stock. This figure reflects her remaining direct holdings following the option exercise and the subsequent sale of 48,044 shares in the open market.

At what prices were the ADPT shares sold in this Form 4 filing?

The reported sale used a weighted average price of $15.30 per share. According to the filing, multiple trades occurred in a price range from $15.11 to $15.54, and detailed trade-by-trade information is available from the reporting person upon request.

What was the exercise price of the options used to acquire ADPT shares?

The stock options were exercised at an exercise price of $3.99 per share for 48,044 shares. The filing notes that the option was fully vested and exercisable at the time of the transaction, enabling conversion into common stock before the subsequent sale.

Was the ADPT insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan. This pre-arranged plan was adopted by Michelle Renee Griffin on November 7, 2025, allowing systematic share sales according to predetermined instructions.

What types of securities are involved in this ADPT Form 4?

The Form 4 reports a derivative security and common stock. The derivative security is a stock option (right to buy), which was exercised into 48,044 shares of Adaptive Biotechnologies common stock before those same 48,044 common shares were sold in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/05/2026 - 08:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GRIFFIN MICHELLE RENEE

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVE E

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/03/2026		M(1)		48,044	A	$3.99	63,438	D
Common Stock	03/03/2026		S(1)		48,044	D	$15.3(2)	15,394	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.99	03/03/2026		M(1)			48,044	(3)	03/03/2034	Common Stock	48,044	$0	0	D

Explanation of Responses:

1. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025.

2. The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.11 to $15.54, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

3. The option is fully vested and exercisable.

	Michelle Griffin by Kyle Piskel, Attorney-in-Fact	03/05/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.